Lecanemab will be examined in early-stage Alzheimer's disease.

Published Date: 16 Jul 2023

The AHEAD study will include cutting-edge elements like blood biomarker screening, novel PET agents, sensitive cognitive outcome scales, dosing tailored to the level of amyloid in the brain, and recruitment strategies to ensure diverse representation.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot